Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy reported two bona fide gift transactions involving common stock on 2026-08-11. A total of 35,000 shares of Guardant Health common stock were transferred from the Helmy A. Eltoukhy Revocable Trust, reducing that trust’s indirect holdings to 1,995,934 shares. On the same date, 35,000 shares were recorded as acquired as indirect holdings of The Eltoukhy Foundation. A footnote states that these entries reflect changes in form of ownership from the revocable trust to The Eltoukhy Foundation, indicating an internal re-titling of shares rather than an open-market purchase or sale.
Guardant Health, Inc. director and Co-Chief Executive Officer AmirAli Talasaz reported internal transfers of common stock interests involving family entities. On 2026-08-10, 75,000 shares were transferred as a bona fide gift from the Talasaz and Eskandari 2017 Family Trust, reducing that indirect holding to 1,824,351 shares, and 75,000 shares were received by The Talasaz Family Foundation, which now holds 75,000 shares. A footnote states these transactions reflect changes in form of ownership between the trust and the foundation.
Guardant Health, Inc. executive John G. Saia, Chief Legal Officer, reported a bona fide gift of 800 shares of common stock on 2026-08-10. The gift reflects a change in form of ownership due to a transfer to a donor-advised fund within the Saia Family Foundation. Following this charitable transfer, Saia directly holds 38,991 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported option exercises and share sales on August 10, 2026. He exercised stock options covering 63,605 shares of common stock, including 35,412 shares at an exercise price of $110.49 per share from an award granted August 3, 2021, which is now fully vested, and 28,193 shares at an exercise price of $28.37 per share from an award granted December 13, 2023 that continues to vest over a three-year period. Freeman then sold 63,605 shares of common stock in open-market transactions at weighted average prices per share ranging from approximately $167.12 to $170.67, with the exact breakdown of shares sold at each price available upon request as noted in the footnotes.
Guardant Health, Inc. shareholder Chris Freeman plans to resell up to 63,605 common shares through Charles Schwab & Co., Inc., with an indicated aggregate market value of $10,786,111.00. The sale is linked to an employee stock option exercise using a broker payment for a cashless exercise on 08/10/2026.
The disclosure also notes a prior sale on 05/22/2026 of 24,406 Guardant Health shares for aggregate proceeds of $2,896,361.00 over the preceding three months.
Guardant Health director Manuel Hidalgo Medina exercised stock options for 950 shares on August 5, 2026 at an exercise price of $32.5500 per share, receiving 950 common shares. He then sold 1,700 common shares in two trades at $163.9450 and $164.6051 per share. After the exercise, he continued to hold stock options covering 12,079 shares that were granted on July 17, 2024 and vest 25% on July 17, 2025, with the remaining 75% vesting monthly over the following three years.
Guardant Health, Inc. director Ian T. Clark exercised stock options and sold shares held through a family trust. On 2026-08-04, options for 2,255 and 6,833 shares of common stock were exercised at strike prices of $91.11 and $50.57. The Thornton-Clark Family Trust then sold a total of 14,180 common shares at weighted average prices of $158.98 and $158.80, within disclosed price ranges.
Manuel Hidalgo Medina filed to sell up to 1,700 shares of Guardant Health, Inc. common stock through Charles Schwab & Co., Inc., to be traded on NASDAQ. The filing lists upcoming share availability from restricted stock lapses and an employee stock option exercise, and notes prior sales of 1,250 and 1,000 shares in the past three months.
Meghan V. Joyce filed a notice relating to potential sales of Guardant Health, Inc. common stock. The filing covers up to 1,803,685 shares to be sold through Charles Schwab & Co., Inc., with an approximate aggregate market value of $134,196,170 and a proposed sale date of 08/05/2026 on NASDAQ.
The notice also lists sales over the prior three months: 10,000 shares for $1,269,809.00 on 06/03/2026, 6,203 shares for $812,604.00 on 06/22/2026, 2,000 shares for $280,045.00 on 06/24/2026, 2,000 shares for $300,082.00 on 06/26/2026, and 4,000 shares for $660,000.00 on 07/01/2026. The securities are described as arising from a restricted stock lapse in connection with equity compensation.